Profile data is unavailable for this security.
About the company
IX Biopharma Ltd. is a Singapore-based specialty pharmaceutical and nutraceutical company. The Company is focused on the development, manufacturing and commercialization of therapies for the treatment of acute and breakthrough pain and other health conditions. Its drug delivery platform technologies are WaferiX, WaferlogiX, and NADiX, which deliver small molecule and biologics. The Company’s segments include Specialty Pharmaceutical and Nutraceutical segments. The Specialty Pharmaceutical segment’s primary business activities are the development and manufacturing of products, and sales of pharmaceutical and medicinal cannabis products. The Nutraceutical segment’s primary business activities are the sale of nutraceutical products.
- Revenue in SGD (TTM)7.23m
- Net income in SGD-5.95m
- Incorporated2004
- Employees56.00
- LocationIX Biopharma Ltd1 Kim Seng Promenade#14-01 Great World City 237994SingaporeSGP
- Phone+65 62352270
- Fax+65 62352170
- Websitehttps://www.ixbiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transcenta Holding Ltd | 1.72m | -48.56m | 177.00m | 171.00 | -- | 1.36 | -- | 103.20 | -0.7402 | -0.7402 | 0.0261 | 1.79 | 0.0075 | 0.3793 | 0.4927 | 57,574.43 | -21.21 | -32.48 | -30.08 | -41.13 | 34.76 | 22.08 | -2,831.15 | -1,072.37 | 0.4387 | -408.75 | 0.2437 | -- | -79.09 | -23.91 | 37.24 | -- | -60.12 | -- |
| Hester Biosciences Ltd | 43.83m | 5.71m | 180.03m | 562.00 | 40.28 | -- | 21.66 | 4.11 | 37.69 | 37.69 | 277.25 | -- | -- | -- | -- | 5,594,555.00 | -- | 5.39 | -- | 6.72 | 73.52 | 64.87 | 13.51 | 11.44 | -- | 9.65 | -- | 23.77 | 2.15 | 11.16 | 45.52 | -1.18 | -22.47 | 1.18 |
| Fuso Pharmaceutical Industries Ltd | 503.66m | -32.40m | 180.65m | 1.34k | -- | 0.5913 | -- | 0.3587 | -467.41 | -467.41 | 7,265.76 | 3,982.82 | 0.7688 | 3.15 | 2.56 | 46,308,210.00 | -4.95 | 0.7682 | -9.87 | 1.29 | 26.19 | 26.94 | -6.43 | 1.05 | 0.7868 | 22.14 | 0.4359 | 106.29 | 9.31 | 5.25 | -338.78 | -- | 4.37 | 6.45 |
| IX Biopharma Ltd | 7.23m | -5.95m | 184.21m | 56.00 | -- | 44.50 | -- | 25.48 | -0.0067 | -0.0067 | 0.0081 | 0.0043 | 0.4991 | 5.46 | 4.11 | -- | -41.06 | -42.93 | -85.83 | -63.02 | 28.05 | 48.40 | -82.27 | -121.27 | 0.9439 | -16.59 | 0.6196 | -- | 30.34 | 51.13 | 6.05 | -- | -27.36 | -- |
| Jilin Provnc Hnn Chnglng Bio-pharm CoLtd | 168.99m | 33.36m | 185.95m | 798.00 | 5.57 | 0.5887 | 4.80 | 1.10 | 0.3678 | 0.3678 | 1.86 | 3.48 | 0.3698 | 2.30 | 3.34 | 1,401,013.00 | 7.30 | 7.46 | 10.54 | 10.45 | 78.95 | 77.80 | 19.74 | 20.45 | 1.42 | -- | 0.0422 | 44.00 | 4.71 | 6.41 | 24.32 | 4.95 | -8.31 | -- |
| 3D Medicines Inc | 81.75m | -30.72m | 187.26m | 183.00 | -- | 1.43 | -- | 2.29 | -0.7745 | -0.7745 | 2.06 | 3.12 | 0.3728 | 7.53 | 6.78 | 2,643,472.00 | -14.79 | -- | -21.47 | -- | 92.11 | -- | -39.68 | -- | 1.59 | -- | 0.205 | -- | -29.81 | -- | 65.19 | -- | -- | -- |
| Syncom Formulations (India) Ltd | 71.80m | 8.79m | 187.79m | 554.00 | 20.77 | 3.56 | 19.71 | 2.62 | 0.69 | 0.69 | 5.56 | 4.03 | 1.24 | 8.89 | 5.41 | 9,296,547.00 | 15.22 | 8.56 | 17.65 | 11.58 | 36.52 | 34.81 | 12.24 | 10.15 | 4.24 | 73.92 | 0.0018 | -- | 76.55 | 17.74 | 95.28 | 28.24 | 41.62 | -- |
| Ngl Fine Chem Ltd | 62.30m | 4.93m | 191.16m | 456.00 | 38.76 | -- | 25.76 | 3.07 | 57.26 | 57.26 | 723.35 | -- | -- | -- | -- | 9,799,871.00 | -- | 13.34 | -- | 17.44 | 51.62 | 41.63 | 7.92 | 12.15 | -- | 9.06 | -- | 2.85 | 8.73 | 19.41 | -48.87 | 20.44 | 53.91 | 0.00 |
| Holder | Shares | % Held |
|---|---|---|
| Pheim Asset Management Sdn. Bhd.as of 30 Jun 2025 | 767.86k | 0.08% |
